GET DAILY SIGNALSProQR Therapeutics (PRQR) Drops -18.8% Over 30 Days: Key Factors Behind the Move
Key Takeaways
- ProQR Therapeutics (PRQR) declined roughly 18.8% over the 30 days through late October, sliding from about $1.65 to $1.34 per share.
- The pullback followed ProQR's research and development day, after which H.C. Wainwright lowered its price target to $8 from $12 while maintaining a Buy rating.
- Over the full quarter, shares are down about 23.9% from late-July levels, despite a mid-August rally that briefly carried the stock above $2.40.
- A dilution overhang tied to a $50 million registered direct offering completed in June 2026 continues to weigh on sentiment.
- Fundamentals remain mixed: second-quarter 2026 revenue rose year over year and the net loss narrowed, but the company is still firmly in investment mode.
- For additional detail, explore ProQR's Price Targets, Earnings, and Forecast pages.
- Discover how AI-driven trading systems approach this ticker on the Trending AI Robots page.
ProQR Therapeutics and Its Place in RNA Editing
ProQR Therapeutics N.V. operates as a clinical-stage biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts. It focuses on RNA therapies through its Axiomer™ platform, which leverages a cell’s own ADAR editing machinery for precise single-nucleotide RNA edits. The goal is to correct disease-causing mutations or adjust protein levels, opening possibilities for both rare and broader conditions.
The lead candidate, AX-0811, targets cholestatic liver diseases and entered Phase 1 with first-patient dosing in September 2026. A partnership with Eli Lilly (LLY) provides added credibility, as the larger firm remains both a shareholder and collaborator. In my view, PRQR’s value hinges on clinical milestones and the broader promise of RNA editing rather than current earnings.
PRQR Stock Performance Over the Past 30 Days and Quarter
From late September into late October 2026, PRQR moved from around $1.65 down to $1.34, representing an 18.8% decline. The path showed a consistent downward drift with occasional selling spikes, leaving the shares near multi-month lows at the close of the period. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking back across the full quarter from late July levels near $1.76, the decline reaches about 23.9%. Volatility marked the stretch, including a sharp mid-August rally that pushed the price briefly above $2.43 before the reversal set in. Overall, the trend reflects sentiment shifts and analyst moves more than any single clinical event.
Drivers Behind the Recent 30-Day Decline
The clearest catalyst came after ProQR’s research and development day, when H.C. Wainwright analyst Ananda Ghosh reduced the price target to $8 from $12 while retaining a Buy rating. The note highlighted ongoing needs around execution, patient selection, biomarkers, and regulatory progress as key considerations.
Financing concerns added pressure. The $50 million registered direct offering completed in June 2026 at $1.81 per share, plus a concurrent $9.2 million placement to Eli Lilly, created a lingering dilution overhang for this pre-revenue biotech. Broader risk appetite for speculative names also softened, and positive updates such as new AI leadership appointments and the AX-0811 dosing start did not fully offset the momentum.
Quarterly Context and Fundamental Progress
Over the quarter, early optimism around the Axiomer platform gave way to more cautious sentiment once the R&D update and target reduction drew attention to execution and regulatory risks. On the financial side, second-quarter 2026 revenue rose to roughly €8.76 million from €3.98 million the prior year, while the net loss improved to approximately €8.73 million from €12.18 million. Even so, ongoing development costs keep the company reliant on external capital, which continues to influence valuation multiples.
Factors to Monitor Going Forward
Clinical updates on AX-0811 will remain central, particularly safety data and enrollment trends from the ongoing Phase 1 trial. Pipeline advancement through the Axiomer platform and any AI-related acceleration efforts also merit attention. Cash position, potential future raises, and outcomes around authorized share capital debates will shape dilution views, while analyst revisions and sector sentiment provide additional context for price action.
Exploring AI-Driven Approaches to PRQR
When reviewing stocks like this, I often look at how automated strategies are positioned. Tickeron’s Trending AI Robots page highlights top-performing bots that track thousands of tickers and can offer a data-driven view on current market dynamics for names such as PRQR.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PRQR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where PRQR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 174 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PRQR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.379) is normal, around the industry mean (3.037). P/E Ratio (-3.350) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders
Industry Biotechnology
Advertisement